home / stock / crdl:cc / crdl:cc quote
Last: | $1.80 |
---|---|
Change Percent: | 4.05% |
Open: | $1.73 |
Close: | $1.73 |
High: | $1.8 |
Low: | $1.69 |
Volume: | 82,631 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.8 | $1.73 | $1.73 | $1.8 | $1.69 | 82,631 | 08-02-2022 |
$1.64 | $1.72 | $1.64 | $1.72 | $1.61 | 242,531 | 05-06-2022 |
$1.72 | $1.79 | $1.72 | $1.79 | $1.66 | 315,483 | 05-05-2022 |
$1.79 | $1.74 | $1.79 | $1.79 | $1.67 | 186,906 | 05-04-2022 |
$1.73 | $1.78 | $1.73 | $1.78 | $1.7 | 145,771 | 05-03-2022 |
$1.78 | $1.75 | $1.78 | $1.83 | $1.73 | 184,836 | 05-02-2022 |
$1.74 | $1.82 | $1.74 | $1.87 | $1.74 | 128,361 | 04-29-2022 |
$1.83 | $1.88 | $1.83 | $1.88 | $1.7 | 228,246 | 04-28-2022 |
$1.8 | $ | $1.8 | $1.96 | $1.8 | 311,603 | 04-27-2022 |
$1.91 | $2.13 | $1.91 | $2.13 | $1.91 | 319,367 | 04-26-2022 |
$2.14 | $2.07 | $2.14 | $2.2 | $1.98 | 380,474 | 04-25-2022 |
$2.1 | $2.11 | $2.1 | $2.15 | $1.95 | 501,993 | 04-22-2022 |
$2.13 | $2.27 | $2.13 | $2.28 | $2.12 | 348,500 | 04-21-2022 |
$2.25 | $2.31 | $2.25 | $2.33 | $2.19 | 316,096 | 04-20-2022 |
$2.3 | $2.23 | $2.3 | $2.39 | $2.15 | 474,595 | 04-19-2022 |
$2.21 | $2.5 | $2.21 | $2.53 | $2.21 | 660,662 | 04-18-2022 |
$2.52 | $2.18 | $2.52 | $2.6 | $2.18 | 1,167,281 | 04-15-2022 |
$2.52 | $2.18 | $2.52 | $2.6 | $2.18 | 1,165,669 | 04-14-2022 |
$2.17 | $2.09 | $2.17 | $2.25 | $2.09 | 325,765 | 04-13-2022 |
$2.08 | $2.05 | $2.08 | $2.14 | $1.96 | 411,779 | 04-12-2022 |
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Inc. Company Name:
CRDL:CC Stock Symbol:
TSXC Market:
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart Fai...
Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients with recurrent pericarditis, with topline results expected in Q2 2024 CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis, which includes recurrent p...
Topline Results Expected in Q2 2024 This is a Designated News Release. Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical ...